Literature DB >> 11299802

Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.

Y Kanoh1, N Ohtani, T Mashiko, S Ohtani, T Nishikawa, S Egawa, S Baba, H Ohtani.   

Abstract

BACKGROUND: In prostate cancer, we previously reported that a marked decrease of serum alpha 2 macroglobulin (alpha 2M) to less than approximately 50 mg/dl was associated with the presence of bone metastases. In order to investigate the relationship between bone metastases and alpha 2M, we assessed these two parameters in 128 patients with prostatic diseases.
MATERIALS AND METHODS: 66 patients with untreated benign prostatic hypertrophy and 62 with untreated prostate cancer were included in the study. Measurement of alpha 2M concentration was performed by Laser-Nephelometry, prostate-specific antigen (PSA) by EIA.
RESULTS: The serum alpha 2M levels in prostate cancer with bone metastases showed a significantly lower level compared with the group without bone metastases (p < 0.01). Cases with serum alpha 2M levels of less than 50 mg/dl all had bone metastases. Serum alpha 2M levels were inversely related to PSA levels in stage M1b disease.
CONCLUSIONS: Measurement of serum alpha 2M levels may be useful for the diagnosis and follow up of bone metastases in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11299802

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses.

Authors:  Uma Kant Misra; Salvatore Vincent Pizzo
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

2.  Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen.

Authors:  Uma K Misra; Sturgis Payne; Salvatore V Pizzo
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

Review 3.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

4.  Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.

Authors:  A Zafeirakis
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

5.  Biometal Dyshomeostasis in Olfactory Mucosa of Alzheimer's Disease Patients.

Authors:  Riikka Lampinen; Veronika Górová; Simone Avesani; Jeffrey R Liddell; Elina Penttilä; Táňa Závodná; Zdeněk Krejčík; Juha-Matti Lehtola; Toni Saari; Juho Kalapudas; Sanna Hannonen; Heikki Löppönen; Jan Topinka; Anne M Koivisto; Anthony R White; Rosalba Giugno; Katja M Kanninen
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

6.  Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia; Thomas B Ledue; Wendy Y Craig
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

7.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.

Authors:  Madhav Thambisetty; Abdul Hye; Catherine Foy; Eileen Daly; Amanda Glover; Allison Cooper; Andrew Simmons; Declan Murphy; Simon Lovestone
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

8.  Serum matrix metalloproteinase-2 levels indicate blood-CSF barrier damage in patients with infectious meningitis.

Authors:  Yuhsaku Kanoh; Tadashi Ohara; Motonari Kanoh; Tohru Akahoshi
Journal:  Inflammation       Date:  2008-01-10       Impact factor: 4.092

9.  Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples.

Authors:  Mark J Bailey; Kristy L Shield-Artin; Karen Oliva; Mustafa Ayhan; Simone Reisman; Gregory E Rice
Journal:  J Carcinog       Date:  2013-06-29

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.